Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-201 Monotherapy and with Pembrolizumab in Advanced Cancer
NCT04659629Phase 1Completed
- Sponsor
- Neurogene Inc.
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, open-label trial of NL-201 in solid tumor (advanced stage), kidney cancer and skin cancer (4 arms), sponsored by Neurogene Inc. Primary endpoints: Recommended Phase 2 Dose, Recommended Dose Schedule and 2 more. Started Apr 2021; status: completed.
02
Drugs
NL-201
03
Conditions
solid tumor (advanced stage)kidney cancerskin cancer
Beyond the preview
Go deeper on NCT04659629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659629.